medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2013-10-27-31medsovet-1119Research ArticleГепатологияHepatologyСовременная диагностика гепатита С и интерпретация результатов выявления маркеров инфицированияDiagnosis of hepatitis c today and interpretation of infection markersКожановаТ. В.KozhanovaT. V.noemail@neicon.ruФГБУ «Институт полиомиелита и вирусных энцефалитов им. М.П. Чумакова» РАМН, Научно-практический центр медпомощи детям Департамента здравоохранения г. МосквыРоссияChumakov Institute of Poliomyelitis and Viral Encephalitides of the RAMS, Scientific and Practical Center of Children's Medical Care, Moscow Healthcare DepartmentRussian Federation2013301220130102731Copyright © Кожанова Т.В., 20132013Кожанова Т.В.Kozhanova T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1119

Вирусный гепатит С является одной из важнейших проблем мирового здравоохранения. Инфекция, вызванная вирусом гепатита С, часто протекает латентно, характеризуется минимальными клиническими проявлениями, а также высокой частотой хронизации. Гепатит С нередко диагностируется случайно, и во многих случаях пациенты остаются недообследованными. Доступные в настоящее время современные методы серологической (определение спектра антител к вирусу гепатита С) и молекулярной диагностики (качественный и количественный анализ выявления РНК вируса гепатита С, генотипирование) гепатита С позволяют выявить инфекцию на ранних сроках, определить необходимость назначения противовирусной терапии, оценить ее эффективность и вероятность достижения устойчивого ответа на лечение. Рассматривается проблема диагностики скрытого гепатита С.

Viral hepatitis C is one of the most pressing global health issues. Infection caused by hepatitis C virus is often latent with minimal clinical manifestations, chracterized by high probability of chronization. Hepatitis C is often diagnosed incidentally; in many cases patients are underdiagnosed. Currently available serological (determining the spectrum of hepatitis C antibodies) and molecular tests (qualitative and quantitative detection of HCV RNA, genotyping) provide for early detection of HCV infection, defining the need for antiviral therapy, evaluation of its effectiveness and chances of achieving a sustained response to treatment. The problem of diagnosing latent hepatitis C is highlighted.

гепатит Свирус гепатита Сантитела к вирусу гепатита СРНК вируса гепатита Сгенотипhepatitis Chepatitis C virushepatitis C RNAgenotypeReferencesDeuffic-Burban S., Deltenre P., Buti M., Stroffolini T. HCV burden in Europe: impact of national treatment practices on future HCV-related morbitidy and mortality through a modeling approach // Hepatol. 2010. Vol. 52. P. 678–679.Deuffic-Burban S., Deltenre P., Buti M., Stroffolini T. HCV burden in Europe: impact of national treatment practices on future HCV-related morbitidy and mortality through a modeling approach // Hepatol. 2010. Vol. 52. P. 678–679.McHutchison J.G. Understanding hepatitis C // Am. J. Manag. Care. 2004. Vol. 10. P. 21–29.McHutchison J.G. Understanding hepatitis C // Am. J. Manag. Care. 2004. Vol. 10. P. 21–29.Scott J., Gretch D. Molecular diagnostics of hepatitis C virus infection: a systematic review // Jama. 2007. Vol. 297. P. 724–732.Scott J., Gretch D. Molecular diagnostics of hepatitis C virus infection: a systematic review // Jama. 2007. Vol. 297. P. 724–732.Шахгильдян И.В., Михайлов М.И., Онищенко Г.Г. Парентеральные вирусные гепатиты (эпидемиология, диагностика, профилактика). М.: ГОУ ВУНМЦ МЗ РФ, 2003.Шахгильдян И.В., Михайлов М.И., Онищенко Г.Г. Парентеральные вирусные гепатиты (эпидемиология, диагностика, профилактика). М.: ГОУ ВУНМЦ МЗ РФ, 2003.Pawlotsky J. Diagnostic testing in hepatitis C virus infection: viral kinetics and genomics // Semin. Liver. Dis. 2003. Vol. 23. P. 3–11.Pawlotsky J. Diagnostic testing in hepatitis C virus infection: viral kinetics and genomics // Semin. Liver. Dis. 2003. Vol. 23. P. 3–11.Colin C., Lanoir D., Touzet S., Meyaud-Kraemer L., Bailly F., Trepo C. Sensitivity and specificity of third-generationColin C., Lanoir D., Touzet S., Meyaud-Kraemer L., Bailly F., Trepo C. Sensitivity and specificity of third-generationDeuffic-Burban S., Deltenre P., Buti M., Stroffolini T. HCV burden in Europe: impact of national treatment practices on future HCV-related morbitidy and mortality through a modeling approach // Hepatol. 2010. Vol. 52. P. 678–679.Deuffic-Burban S., Deltenre P., Buti M., Stroffolini T. HCV burden in Europe: impact of national treatment practices on future HCV-related morbitidy and mortality through a modeling approach // Hepatol. 2010. Vol. 52. P. 678–679.McHutchison J.G. Understanding hepatitis C // Am J Manag Care. 2004. Vol. 10. P. 21–29.McHutchison J.G. Understanding hepatitis C // Am J Manag Care. 2004. Vol. 10. P. 21–29.Scott J., Gretch D. Molecular diagnostics of hepatitis C virus infection: a systematic review // Jama. 2007. Vol. 297. P. 724–732.Scott J., Gretch D. Molecular diagnostics of hepatitis C virus infection: a systematic review // Jama. 2007. Vol. 297. P. 724–732.Шахгильдян И.В., Михайлов М.И., Онищенко Г.Г. Парентеральные вирусные гепатиты (эпидемиология, диагностика, профилактика). М.: ГОУ ВУНМЦ МЗ РФ, 2003. 384 с.Шахгильдян И.В., Михайлов М.И., Онищенко Г.Г. Парентеральные вирусные гепатиты (эпидемиология, диагностика, профилактика). М.: ГОУ ВУНМЦ МЗ РФ, 2003. 384 с.Pawlotsky J. Diagnostic testing in hepatitis C virus infection: viral kinetics and genomics // Semin Liver Dis. 2003. Vol. 23. P. 3–11.Pawlotsky J. Diagnostic testing in hepatitis C virus infection: viral kinetics and genomics // Semin Liver Dis. 2003. Vol. 23. P. 3–11.Colin C., Lanoir D., Touzet S., Meyaud-Kraemer L., Bailly F., Trepo C. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature // J. Viral. Hepat. 2001. Vol. 8. P. 87–95.Colin C., Lanoir D., Touzet S., Meyaud-Kraemer L., Bailly F., Trepo C. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature // J. Viral. Hepat. 2001. Vol. 8. P. 87–95.Terrault N., Pawlotsky J., McHutchison J., Krajden M., Gordon S., Zitron I., Perrillo R., Gish R., Holodniy M., Friesenhahn M. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy // J. Viral. Hepat. 2005. Vol. 12. P. 465–472.Terrault N., Pawlotsky J., McHutchison J., Krajden M., Gordon S., Zitron I., Perrillo R., Gish R., Holodniy M., Friesenhahn M. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy // J. Viral. Hepat. 2005. Vol. 12. P. 465–472.Ghany M., Strader D., Thomas D. Seeff L. Diagnosis, management and treatment of hepatitis C: an update // Hepatol. 2009. Vol. 49. P. 1335–1374.Ghany M., Strader D., Thomas D. Seeff L. Diagnosis, management and treatment of hepatitis C: an update // Hepatol. 2009. Vol. 49. P. 1335–1374.Fried M., Shiffman M., Reddy K., Smith C., Marinos G., Gonçales F., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection // N. Engl. J. Med. 2002. Vol. 347. P. 975–982.Fried M., Shiffman M., Reddy K., Smith C., Marinos G., Gonçales F., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection // N. Engl. J. Med. 2002. Vol. 347. P. 975–982.Hadziyannis S., Sette H., Morgan T., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer H., Bernstein D., Rizzetto M., Zeuzem S., Pockros P., Lin A., Ackrill A. Peginterferon-[alpha] 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose // Ann. Intern. Med. 2004. Vol. 140. P. 346–355.Hadziyannis S., Sette H., Morgan T., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer H., Bernstein D., Rizzetto M., Zeuzem S., Pockros P., Lin A., Ackrill A. Peginterferon-[alpha] 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose // Ann. Intern. Med. 2004. Vol. 140. P. 346–355.Manns M., McHutchinson J., Gordon S., Rustgi V., Shiffman M., Reindollar R., Goodman Z., Koury K., Ling M., Albrecht J. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial // Lancet. 2001. Vol. 358. P. 958–965.Manns M., McHutchinson J., Gordon S., Rustgi V., Shiffman M., Reindollar R., Goodman Z., Koury K., Ling M., Albrecht J. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial // Lancet. 2001. Vol. 358. P. 958–965.McHutchison J., Gordon S., Schiff E., Shiffman M., Lee W., Rustgi V., Goodman Z., Ling M., Cort S., Albrecht J. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C // N Engl J Med. 1998. Vol. 339. P. 1485-1492.McHutchison J., Gordon S., Schiff E., Shiffman M., Lee W., Rustgi V., Goodman Z., Ling M., Cort S., Albrecht J. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C // N Engl J Med. 1998. Vol. 339. P. 1485-1492.Sarrazin C., Gartner B., Sizmann D., Babiel R., Mihm U., Hofmann W., von Wagner M., Zeuzem S. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5 // J Clin Microbiol. 2006. Vol. 44. P. 729-737.Sarrazin C., Gartner B., Sizmann D., Babiel R., Mihm U., Hofmann W., von Wagner M., Zeuzem S. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5 // J Clin Microbiol. 2006. Vol. 44. P. 729-737.Jensen D., Morgan T., Marcellin P., Pockros P., Reddy K., Hadziyannis S., Ferenci P., Ackrill A., Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy // Hepatol. 2006. Vol. 43. P. 954-960.Jensen D., Morgan T., Marcellin P., Pockros P., Reddy K., Hadziyannis S., Ferenci P., Ackrill A., Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy // Hepatol. 2006. Vol. 43. P. 954-960.NIH Consensus and State-of-the-Science Statements. Management of Hepatitis C. 2002. Vol.19. P. 1-46. http://consensus.nih.gov/2002/2002 Hepatitis C 2002 116 main.htm 01.08.2013.NIH Consensus and State-of-the-Science Statements. Management of Hepatitis C. 2002. Vol.19. P. 1-46. http://consensus.nih.gov/2002/2002 Hepatitis C 2002 116 main.htm 01.08.2013.Jacobson I., McHutchison J., Dusheiko G., Di Bisceglie A., Reddy K., Bzowej N., Marcellin P., Muir A., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R., Yoshida E., Adda N., Bengtsson L., Sankoh A., Kieffer T., George S., Kauffman R., Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection // N Engl J Med. 2011. Vol. 364. P. 2405-2416.Jacobson I., McHutchison J., Dusheiko G., Di Bisceglie A., Reddy K., Bzowej N., Marcellin P., Muir A., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R., Yoshida E., Adda N., Bengtsson L., Sankoh A., Kieffer T., George S., Kauffman R., Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection // N Engl J Med. 2011. Vol. 364. P. 2405-2416.Poordad F., McCone J., Bacon B., Bruno S., Manns M., Sulkowski M., Jacobson I., Reddy K., Goodman Z., Boparai N., DiNubile M., Sniukiene V., Brass C., Albrecht J., Bronowicki J. Boceprevir for untreated chronic HCV genotype 1 infection // N Engl J Med. 2011. Vol. 364. P. 1195-1206.Poordad F., McCone J., Bacon B., Bruno S., Manns M., Sulkowski M., Jacobson I., Reddy K., Goodman Z., Boparai N., DiNubile M., Sniukiene V., Brass C., Albrecht J., Bronowicki J. Boceprevir for untreated chronic HCV genotype 1 infection // N Engl J Med. 2011. Vol. 364. P. 1195-1206.Thomas H., Lemon S., Zuckerman A. Viral hepatitis. Wiley-Blackwell. Third edition. 2005. – P. 896.Thomas H., Lemon S., Zuckerman A. Viral hepatitis. Wiley-Blackwell. Third edition. 2005. – P. 896.Castillo I., Pardo M., Bartolomi J., Ortiz-Movilla N., Rodrнguez-Iсigo E., de Lucas S., Salas C., Jimйnez-Heffernan J., Pйrez-Mota A., Graus J., Lуpez-Alcorocho J., Carreсo V. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown // J Infect Dis. 2004. Vol. 189. P. 7-14.Castillo I., Pardo M., Bartolomi J., Ortiz-Movilla N., Rodrнguez-Iсigo E., de Lucas S., Salas C., Jimйnez-Heffernan J., Pйrez-Mota A., Graus J., Lуpez-Alcorocho J., Carreсo V. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown // J Infect Dis. 2004. Vol. 189. P. 7-14.Castillo I., Rodriguez – Inigo E. Bartolomé J, Pardo M, Carreño V. Comparative study on the clinical and virological characteristics among patients with single occult hepatitis B virus (HBV), single occult hepatitis C virus (HCV) and occult HBV and HCV dual infection // J Med Virol. 2007. Vol. 79. P. 239-241.Castillo I., Rodriguez – Inigo E. Bartolomé J, Pardo M, Carreño V. Comparative study on the clinical and virological characteristics among patients with single occult hepatitis B virus (HBV), single occult hepatitis C virus (HCV) and occult HBV and HCV dual infection // J Med Virol. 2007. Vol. 79. P. 239-241.Jain P., Nijhawan S. Occult hepatitis C virus infection is more common then hepatitis B infection in maintenance hemodialysis patients // World J Gastroenter. 2008. Vol. 14. P. 2288-2289.Jain P., Nijhawan S. Occult hepatitis C virus infection is more common then hepatitis B infection in maintenance hemodialysis patients // World J Gastroenter. 2008. Vol. 14. P. 2288-2289.Rai R., Mathur A. Udawat HP, Nepalia S, Nijhawan S, Mathur A. et al. Prevalence of occult hepatitis B and C HIV patients infected through sexual transmission // Trop Gastroenterol. 2007. Vol. 28. P. 19-23.Rai R., Mathur A. Udawat HP, Nepalia S, Nijhawan S, Mathur A. et al. Prevalence of occult hepatitis B and C HIV patients infected through sexual transmission // Trop Gastroenterol. 2007. Vol. 28. P. 19-23.Pham T., Michalak T. Occult persistence and lymphotropism of hepatitis C virus infection // World J Gastroenterol. 2008. Vol. 14. P. 2789-2793.Pham T., Michalak T. Occult persistence and lymphotropism of hepatitis C virus infection // World J Gastroenterol. 2008. Vol. 14. P. 2789-2793.Carreno V. Occult hepatitis C virus infection: a new from of hepatitis C // World J Gastroenterol. 2006. Vol. 12. P. 6922-6925.Carreno V. Occult hepatitis C virus infection: a new from of hepatitis C // World J Gastroenterol. 2006. Vol. 12. P. 6922-6925.Pardo M., Lуpez-Alcorocho J., Castillo I., Rodrнguez-Iсigo E., Perez-Mota A., Carreсo V. Effect of anti-viral therapy for occult hepatitis C virus infection // Aliment Pharmacol Ther. 2006. Vol. 23. P. 1153–1159.Pardo M., Lуpez-Alcorocho J., Castillo I., Rodrнguez-Iсigo E., Perez-Mota A., Carreсo V. Effect of anti-viral therapy for occult hepatitis C virus infection // Aliment Pharmacol Ther. 2006. Vol. 23. P. 1153–1159.

The authors declare that there are no conflicts of interest present.